Braidwell LP Buys New Shares in CeriBell (NASDAQ:CBLL)

Braidwell LP purchased a new position in CeriBell (NASDAQ:CBLL - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 210,000 shares of the company's stock, valued at approximately $5,435,000. Braidwell LP owned 0.59% of CeriBell as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Legal & General Group Plc bought a new stake in shares of CeriBell in the 4th quarter worth approximately $32,000. Summit Investment Advisors Inc. acquired a new stake in CeriBell during the fourth quarter worth $33,000. Tower Research Capital LLC TRC bought a new stake in CeriBell in the 4th quarter valued at $37,000. BNP Paribas Financial Markets acquired a new position in shares of CeriBell in the 4th quarter valued at $43,000. Finally, PNC Financial Services Group Inc. bought a new position in shares of CeriBell during the 4th quarter worth about $47,000.

Insider Buying and Selling

In related news, CEO Xingjuan Chao sold 5,700 shares of CeriBell stock in a transaction on Thursday, April 17th. The stock was sold at an average price of $15.02, for a total transaction of $85,614.00. Following the completion of the sale, the chief executive officer now directly owns 746,451 shares of the company's stock, valued at $11,211,694.02. The trade was a 0.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 24,700 shares of company stock valued at $372,434 over the last ninety days.

CeriBell Stock Down 6.6 %

NASDAQ:CBLL traded down $1.13 during mid-day trading on Friday, reaching $15.97. 468,171 shares of the company were exchanged, compared to its average volume of 272,942. CeriBell has a 12 month low of $10.01 and a 12 month high of $32.75. The firm's fifty day moving average is $18.06.

CeriBell (NASDAQ:CBLL - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. As a group, equities analysts predict that CeriBell will post -2.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Canaccord Genuity Group reissued a "buy" rating and issued a $33.00 price target on shares of CeriBell in a research report on Wednesday, February 26th. LADENBURG THALM/SH SH started coverage on CeriBell in a research report on Friday, April 4th. They set a "buy" rating and a $32.00 target price for the company. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $32.50.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.